Thrombosis Male Female BMI (kg/m2) 30.0–34.9 35.0–39.9 40.0–44.9 45.0–49.9 >50.0 Table 6: Diagnosed events of VTE and PE during the ﬁrst 90 postoperative days in dependence on gender and BMI. VTE risk (95% conﬁdence interval) (%) 0.09 (0.02–0.27) 0.06 (0.02–0.14) 0.00 (—) 0.00 (—) 0.07 (0.01–0.26) 0.11 (0.02–0.32) 0.06 (0.01–0.19) VTE relative risk (95% conﬁdence interval) (%) 1.3691 (0.5594–3.3509) 0.8608 (0.5032–1.4725) 1.129 1.682 1.000 P 0.5085 0.3090 PE risk (95% conﬁdence interval) (%) 0.12 (0.03–0.31) 0.08 (0.03–0.17) 0.00 (—) 0.00 (—) 0.04 (0.00–0.20) 0.18 (0.06–0.42) 0.11 (0.03–0.25) PE relative risk (95% conﬁdence interval) (%) 1.3242 (0.6056–2.8953) 0.8773 (0.5611–1.3715) 0.342 (0.040–2.929) 1.697 (0.491–5.866) 1.000 P 0.5216 0.7783 5 (iv) venous insuﬃciency, (v) hypoventilation syndrome, (vi) smoking, and (vii) thrombosis in the medical history. However, evidence-based data on the recommendations mentioned above are lacking. Therefore, randomized or observational studies with large number of cases are required to optimize medication and mechanical and interventional prophylaxis for thromboembolism [9, 16, 35, 36]. Abbreviations BIB: Intragastric balloon BPD: Biliopancreatic diversion GB: Gastric banding DS: Duodenal switch NMH: Heparin of low molecular weight PE: Pulmonary embolism RYGBP: Roux-en-Y gastric bypass SG: Sleeve gastrectomy VTE: Deep venous thrombosis. Acknowledgments German Surgery Registry has been supported by BMBF since 2012. The authors acknowledge Bariatric Surgery Working Group, Competence Network Obesity. References [1] P. T. James, N. Rigby, and R. Leach, “The obesity epidemic, metabolic syndrome and future prevention strategies,” Euro- pean Journal of Cardiovascular Prevention and Rehabilitation, vol. 11, no. 1, pp. 3–8, 2004. [2] M. Deitel, “Overweight and obesity worldwide now estimated to involve 1.7 Billion people,” Obesity Surgery, vol. 13, no. 3, pp. 329–330, 2003. [3] Statistisches-Bundesamt, Mikrozensus: Statistisches Bunde- samt. Federal Statistical Oﬃce. 2010 Microcensus. Wiesbaden: Federal Statistical Oﬃce. [4] P. T. Katzmarzyk, C. L. Craig, and C. Bouchard, “Original article underweight, overweight and obesity: relationships with mortality in the 13-year follow-up of the Canada Fitness Survey,” Journal of Clinical Epidemiology, vol. 54, no. 9, pp. 916–920, 2001. [5] T. von Lengerke, P. Reitmeir, and J. John, “Direct medical costs of (severe) obesity: a bottom-up assessment of over- vs. normal-weight adults in the KORA-study region (Augsburg, Germany),” Gesundheitswesen, vol. 68, no. 2, pp. 110–115, 2006. [6] Langfassung dieser Leitlinie, “Prophylaxe der VTE,” http:// www.leitlinien.net/003-001l. [7] Clinical Issues Committee of the American Society for Metabolic and Bariatric Surgery, “Prophylactic measures to reduce the risk of venous thromboembolism in bariatric surgery patients,” Surgery for Obesity and Related Diseases, vol. 3, no. 5, pp. 494–495, 2007. [8] L. F. Martin and B. P. Gouda, “What we know and don’t know about deep venous thrombosis and pulmonary embolism!,” Obesity Surgery, vol. 15, no. 4, pp. 565–566, 2005. [9] C. Becattini, G. Agnelli, G. Manina, G. Noya, and F. Ron- delli, “Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention,” Surgery for Obesity and Related Diseases, vol. 8, no. 1, pp. 108– 115, 2012. [10] C. Stroh, R. Weiner, and T. Horbach, “Aktuelle daten der qualita¨tssicherungsstudie f u¨r operative therapie der adipositas in Deutschland,” Zentralbl Chir. In press. [11] G. G. Hamad and P. S. Choban, “Enoxaparin for thrombo- prophylaxis in morbidly obese patients undergoing bariatric surgery: ﬁndings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study,” Obesity Surgery, vol. 15, no. 10, pp. 1368–1374, 2005. [12] B. K. Poulose, M. R. Griﬃn, Y. Zhu et al., “National analysis of adverse patient safety events in bariatric surgery,” American Surgeon, vol. 71, no. 5, pp. 406–413, 2005. [13] D. V. Gugliotti, “What is the optimal venous thromboem- bolism prophylaxis for patients undergoing bariatric surgery? IMPACT consults. Proceedings of the 2nd Annual Cleveland Clinic Perioperative Medicine Summit,” Cleveland Clinic Journal of Medicine, vol. 73, pp. S17–18, 2006. [14] E. J. DeMaria, D. Portenier, and L. Wolfe, “Obesity surgery mortality risk score: proposal for a clinically useful score to predict mortality risk in patients undergoing gastric bypass,”